| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PXMD | Common Stock | Sale | -$23.8K | -13.8K | -3.89% | $1.72 | 342K | Mar 6, 2023 | Direct | F1, F2 |
| transaction | PXMD | Common Stock | Sale | -$23.5K | -15.1K | -4.43% | $1.55 | 327K | Mar 7, 2023 | Direct | F1, F3 |
| holding | PXMD | Common Stock | 7.34M | Mar 6, 2023 | TardiMed Sciences, LLC | F4 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. |
| F2 | This sale price represents the weighted average sale price of the shares sold ranging from $1.90 to $1.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| F3 | This sale price represents the weighted average sale price of the shares sold ranging from $1.67 to $1.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| F4 | The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |